Delivery of Potential Drugs to The Colon: Challenges and Strategies

  • Raditya Iswandana Laboratory of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.
  • Kurnia Sari Setio Putri Laboratory of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.
  • Sekar Arum Larasati Laboratory of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.
  • Maxius Gunawan Laboratory of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.
  • Fathia Amalia Putri Laboratory of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.
Keywords: active compound, challenges, colon, colon-targeted drug delivery systems, strategies


Colon-targeted drug delivery systems have been exploited to treat local diseases in the colon, systemic delivery of protein and peptide, and chronotherapeutic drugs. The upper gastrointestinal tract restricts the effective delivery of these drugs. Therefore, several strategies are needed for targeted drugs directly to the colon, such as pH-sensitive polymers, enzyme-sensitive polymers, bacterially degradable polysaccharides, time-dependent polymers, and particulate systems. However, variable physiological conditions of the gastrointestinal tract in individuals cause combinations of these strategies are needed to ensure colonic delivery of the drug. This review presents and discusses several potential drugs and their approaches used to design and develop colon-targeted drug delivery systems for medications with particular characteristics.

Author Biography

Raditya Iswandana, Laboratory of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.




Agüero L., Zaldivar-Silva D., Peña L., & Dias ML., 2017. Alginate microparticles as oral colon drug delivery device: A review. Carbohydr. Polym. 168: 32–43.
Ali H., Weigmann B., Neurath MF., Collnot EM., Windbergs M., & Lehr CM., 2014. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J. Control. Release. 183: 167–177.
Amidon S, Brown JE., & Dave VS., 2015. Colon-targeted oral drug delivery systems: Design trends and approaches. AAPS PharmSciTech. 16(4): 731–741.
Ballesta A., Innominato PF., Dallmann R., Rand DA., & Lévi FA., 2017). Systems chronotherapeutics. Pharmacol. Rev. 69(2): 161–199.
Cesar ALA., Abrantes FA., Farah L., Castilho RO., Cardoso V., Fernandes SO., Araújo ID., & Faraco AAG., 2018. New mesalamine polymeric conjugate for controlled release: Preparation, characterization and biodistribution study. Eur. J. Pharm. Sci. 111: 57–64.
Cook MT., Tzortzis G., Charalampopoulos D., & Khutoryanskiy VV., 2012. Microencapsulation of probiotics for gastrointestinal delivery. J. Control. Release. 162(1): 56–67.
Date AA., Hanes J., & Ensign LM., 2016. Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. J. Control. Release. 240: 504–526.
Elkhodairy KA., Elsaghir HA., & Al-Subayiel AM., 2014. Formulation of indomethacin colon targeted delivery systems using polysaccharides as carriers by applying liquisolid technique. BioMed. Res. Int. 2014: 1–17.
Elsayed AM., 2012. Oral delivery of insulin: Novel approaches. IntechOpen.
Eun CS., & Han DS., 2015. Does the cyclosporine still have a potential role in the treatment of acute severe steroid-refractory ulcerative colitis? Gut Liver. 9(5): 567-568.
Fang Y., Wang Q., Lin X., Jin X., Yang D., Gao S., Wang X., Yang M., & Shi K., 2019. Gastrointestinal responsive polymeric nanoparticles for oral delivery of insulin: optimized preparation, characterization, and in vivo evaluation. J. Pharm. Sci. 108(9): 2994–3002.
Goodman LS., & Gilman A., 2011. Anti-inflammatory, Antipyretic, and Analgesic Agents; Pharmacotherapy of Gout. In The Pharmacological Basis of Therapeutics (12th ed., p. 985). McGraw Hill.
Handali S., Moghimipour E., Rezaei M., Ramezani Z., Kouchak M., Amini M., Angali KA., Saremy S., & Dorkoosh FA., 2018. A novel 5-Fluorouracil targeted delivery to colon cancer using folic acid conjugated liposomes. Biomed. Pharmacother. 108: 1259–1273.
Iswandana R., Putri KSS., Dwiputra R., Yanuari T., Sari SP., & Djajadisastra J. (2017a). Formulation of chitosan tripolyphosphate-tetrandrine beads using ionic gelation method: In vitro and in vivo evaluation. Int. J. Appl. Pharm. 9(5): 109–115.
Iswandana R., Putri KSS., Sandiata CE., Triani S., Sari SP., & Djajadisastra J., 2017b. Formulation of tetrandrine beads using ionic gelation method ca-pectinate coated ph-sensitive polymers as colon-targeted dosage form. Asian J. Pharm. Clin. Res. 10(10): 90.
Iswandana R., Putri KSS., Wulandari FR., Najuda G., Sari SP., & Djajadisastra J., 2018. Preparation of calcium alginate-tetrandrine beads using ionic gelation method as colon-targeted dosage form. J. Appl. Pharm. Sci. 8(5): 68–74.
Iwao Y., Tomiguchi I., Domura A., Mantaira Y., Minami A., Suzuki T., Ikawa T., Kimura S., & Itai S., 2018. Inflamed site-specific drug delivery system based on the interaction of human serum albumin nanoparticles with myeloperoxidase in a murine model of experimental colitis. Eur. J. Pharm. Biopharm. 125: 141–147.
Jain D., Verma S., & Shukla S., 2012. Formulation and characterization of calcium chloride guar gum microsphere of theophylline. Chron. Young Sci. 3(2): 137.
Leuva VR., Patel BG., Chaudhary DJ., Patel JN., & Modasiya MMK., 2012. Oral colon specific drug delivery system. J. Pharm. Res. 5(4): 2293–2297.
Lu L., Chen G., Qiu Y., Li M., Liu D., Hu D., Gu X., & Xiao Z., 2016. Nanoparticle-based oral delivery systems for colon targeting: principles and design strategies. Sci. Bull. 61(9): 670–681.
Ma Z., Ma R., Wang X., Gao J., Zheng Y., & Sun Z., 2019. Enzyme and PH responsive 5-flurouracil (5-FU) loaded hydrogels based on olsalazine derivatives for colon-specific drug delivery. Eur. Polym. J. 118: 64–70.
Macedo A., Filipe P., Thomé NG., Vieira J., Oliveira C., Teodósio C., Ferreira R., Roque L., & Fonte P., 2020. A brief overview of the oral delivery of insulin as an alternative to the parenteral delivery. Curr. Mol. Med. 20(2): 134–143.
Melero A., Draheim C., Hansen S., Giner E., Carreras JJ., Talens-Visconti R., Garrigues TM., Peris JE., Recio MC., Giner R., & Lehr CM., 2017. Targeted delivery of cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. Eur. J. Pharm. Biopharm. 119: 361–371.
Morales-Burgos AM., Carvajal-Millan E., Rascón-Chu A., Martínez-López AL., Lizardi-Mendoza J., López-Franco YL., & Brown-Bojorquez F., 2019. Tailoring reversible insulin aggregates loaded in electrosprayed arabinoxylan microspheres intended for colon-targeted delivery. J. Appl. Polym. Sci. 136(38): 1–8.
Naeem M., Bae J., Oshi, AM., Kim MS., Moon HR., Lee BL., Im E., Jung Y., & Yoo JW., 2018. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis. Int. J. Nanomed. 13: 1225–1240.
Naeem M., Cao J., Choi M., Kim WS., Moon HR., Lee BL., Kim MS., Jung Y., & Yoo JW., 2015. Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles. Int. J. Nanomed. 10: 4565–4580.
Newton AMJ., Indana VL., & Kumar J., 2015. Chronotherapeutic drug delivery of tamarind gum, chitosan and okra gum controlled release colon targeted directly compressed propranolol hcl matrix tablets and in-vitro evaluation. Int. J. Biol. Macromol. 79: 290–299.
Patel MM., & Amin AF., 2011. Design and optimization of colon-targeted system of theophylline for chronotherapy of nocturnal asthma. J. Pharm. Sci. 100(5), 1760–1772.
Patel MM., 2013. Colon targeting: an emerging frontier for oral insulin delivery. Expert Opin. Drug Deliv. 10(6): 731–739.
Philip A., & Philip B., 2010. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med. J. 25(2): 70–78.
Pithadia AB., & Jain S., 2011. Treatment of inflammatory bowel disease (IBD). Pharmacol. Rep. 63(3): 629–642.
Quetglas EG., Armuzzi A., Wigge S., Fiorino G., Barnscheid L., Froelich M., & Danese S., 2015. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur. J. Clin. Pharmacol. 71(7): 773–799.
Rekha MR., & Sharma CP., 2011. Chapter 8. Nanoparticle mediated oral delivery of peptides and proteins: Challenges and perspectives, edited by Chris Van Der Walle. Peptide and Protein Delivery. Academic Press. pp. 165–194.
Roberts LK., Barr LJ., Fuller DH., McMahon CW., Leese PT., & Jones S., 2005. Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. Vaccine. 23(40): 4867–4878.
Sahu KK., Kaurav M., & Pandey RS., 2019. Chylomicron mimicking solid lipid nanoemulsions encapsulated enteric minicapsules targeted to colon for immunization against hepatitis B. Int. Immunopharmacol. 66: 317–329.
Sahu KK., & Pandey RS., 2019. Development and characterization of HBsAg-loaded Eudragit nanoparticles for effective colonic immunization. Pharm. Dev. Tech. 24(2): 166–175.
Salvioni L., Fiandra L., Del Curto MD., Mazzucchelli S., Allevi R., Truffi M., Sorrentino L., Santini B., Cerea M., Palugan L., Corsi F., & Colombo M., 2016. Oral delivery of insulin via polyethylene imine-based nanoparticles for colonic release allows glycemic control in diabetic rats. Pharmacol. Res. 110: 122–130.
Sandborn WJ., Travis S., Moro L., Jones R., Gautille T., Bagin R., Huang M., Yeung P., & Ballard ED., 2012. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE i study. Gastroenterology. 143(5): 1218-1226.e2.
Sardo HS., Saremnejad F., Bagheri S., Akhgari A., Afrasiabi Garekani H., & Sadeghi F., 2019. A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems. Int. J. Pharm. 558: 367–379.
Shahiwala A., 2020. Cyclodextrin conjugates for colon drug delivery. J. Drug Del. Sci. Tech. 55: 101448.
Sharma N., Sharma A., Bhatnagar A., Nishad D., Karwasra R., Khanna K., Sharma D., Kumar N., & Jain GK., 2019. Novel gum acacia based macroparticles for colon delivery of Mesalazine: Development and gammascintigraphy study. J. Drug Del. Sci. Tech. 54, 101224.
Tromm A., Bunganič I., Tomsová E., Tulassay Z., Lukáš M., Kykal J., Bátovský M., Fixa B., Gabalec L., Safadi R., Kramm H., Altorjay I., Löhr H., Koutroubakis I., Bar–Meir S., Štimac D., Schäffeler E., Glasmacher C., Dilger K., … Greinwald R., 2011. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active crohn’s disease. Gastroenterology. 140(2): 425-434.e1.
Tummala S., Satish Kumar MN., & Prakash A, 2015. Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm. J., 23(3): 308–314.
Verma A., Kumar N., Malviya R., & Sharma PK., 2014. Emerging trends in noninvasive insulin delivery. J. Pharm. 2014: 1–9.
Westra IM., Oosterhuis D., Groothuis GMM., & Olinga P., 2014. Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs. Toxicol. Appl. Pharmacol. 274(2): 328–338.
Yassin AEB., Aodah AH., Al-Suwayeh S., & Taha EI., 2012. Theophylline colon specific tablets for chronotherapeutic treatment of nocturnal asthma. Pharm. Dev. Tech. 17(6): 712–718.
Ye B., & van Langenberg DR., 2015. Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal? World J. Gastrointest. Pharmacol. Ther. 6(4): 137.
Yoo JW., Naeem M., Choi M., Cao J., Yoon S., Kim MS., Jung Y., Lee J., Moon HR., Ikram M., & Lee Y., 2015. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Drug Des. Devel. Ther. 9: 3789-3799
Yun Y., Cho YW., & Park K., 2013. Nanoparticles for oral delivery: Targeted nanoparticles with peptidic ligands for oral protein delivery. Adv. Drug Del. Rev. 65(6): 822–832.
How to Cite
Iswandana, R., Putri, K. S. S., Larasati, S. A., Gunawan, M., & Putri, F. A. (2022). Delivery of Potential Drugs to The Colon: Challenges and Strategies. Indonesian Journal of Pharmacy, 33(3), 307-332.
Review Article